Fjarde AP Fonden Fourth Swedish National Pension Fund Reduces Position in Kenvue Inc. (NYSE:KVUE)

Fjarde AP Fonden Fourth Swedish National Pension Fund decreased its holdings in Kenvue Inc. (NYSE:KVUE) by 6.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 479,632 shares of the company’s stock after selling 32,400 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Kenvue were worth $10,240,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of KVUE. Huntington National Bank lifted its position in Kenvue by 26.5% during the third quarter. Huntington National Bank now owns 4,161 shares of the company’s stock valued at $96,000 after purchasing an additional 871 shares during the period. ING Groep NV raised its stake in Kenvue by 23.6% during the 3rd quarter. ING Groep NV now owns 3,576,616 shares of the company’s stock valued at $82,727,000 after buying an additional 681,954 shares during the last quarter. Handelsbanken Fonder AB lifted its holdings in shares of Kenvue by 2.9% during the 4th quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company’s stock valued at $15,846,000 after buying an additional 21,222 shares during the period. Alberta Investment Management Corp boosted its stake in shares of Kenvue by 23.2% in the 4th quarter. Alberta Investment Management Corp now owns 582,895 shares of the company’s stock worth $12,445,000 after buying an additional 109,700 shares during the last quarter. Finally, Empower Advisory Group LLC bought a new stake in shares of Kenvue in the fourth quarter worth $48,252,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of Kenvue stock opened at $23.31 on Monday. The stock’s 50-day simple moving average is $21.31 and its 200-day simple moving average is $22.20. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The company has a market capitalization of $44.68 billion, a price-to-earnings ratio of 43.97, a PEG ratio of 2.62 and a beta of 1.45.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.52%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Wall Street Analyst Weigh In

KVUE has been the topic of a number of recent research reports. Canaccord Genuity Group lowered their target price on Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. UBS Group reduced their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Finally, Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.